Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study

BACKGROUND: The physical tolerance in the advanced non-small cell lung cancer (NSCLC) patient often deteriorates, with a limited effective rate of the third-line treatment. This study retrospectively analyzed the efficacy and safety of etoposide soft capsules combined with anlotinib in the third-lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yi-Jun, Qiu, Yan-Ru, Lin, Jian-Guang, Dai, Yang-Bin, Su, Yun-Xia, Yamada, Tadaaki, Uematsu, Shugo, Xu, Tian-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636436/
https://www.ncbi.nlm.nih.gov/pubmed/37969289
http://dx.doi.org/10.21037/jtd-23-1412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636436/
https://www.ncbi.nlm.nih.gov/pubmed/37969289
http://dx.doi.org/10.21037/jtd-23-1412

Ejemplares similares